

# Guideline Amendment Summary

## Diagnosis and Treatment of Early Stage Testicular Cancer

Published 2019; Amended 2023

The changes below constitute updates made in the 2023 Amendment:

Section	Document Update
Methodology	The methodology section was updated to note updated search dates and amendment peer review details.
Statement #18	References updated to support the role of MRI in surveillance/staging of TGCT patients. Statement changed from “must” to “should” as well as replaced “CT scan” with “cross-sectional imaging”.
Statement #27	Statement broken up into three sub statements. RPLND was added to the statement as a treatment option. Supporting text was updated accordingly.
Statement #37	Statement restructured. Supporting text updated to include long-term follow up for 2 cycles of EP without bleomycin.
Statement #38	Statement upgraded from “moderate” to “strong”. Updated imaging timeline recommendations.
Statement 43	Survivorship section was rewritten. Old statements 43-45 combined into new statement 43 along with updates to supporting text.
References	The reference list was updated to reflect document additions and deletions.

Note: Additional editorial changes were made throughout the guideline to align with current AUA guideline criteria and for consistency purposes. These additional changes were not substantial and were not content-related.